Tango Therapeutics Expands Board of Directors with the Addition of
Leading Oncology Experts with Deep Experience in Targeted and
Personalized Therapies

March 08, 2018 08:00 AM Eastern Daylight Time

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Tango Therapeutics, a biotechnology company creating novel, targeted
medicines for specific cancer subtypes, today announced the addition of
three experienced leaders with deep backgrounds in personalized cancer
research, drug discovery and development to the board of directors.

“Their expertise, insights and
commitment to this field will help Tango immensely as we create a new
generation of breakthrough cancer therapies.”

Joining the board are Michael Pellini, M.D., MBA, chairman of Foundation
Medicine and managing partner at Section 32; Allen Oliff, M.D., an
oncologist and senior vice president in research and development at
GlaxoSmithKline; and Pablo Cagnoni, M.D., the president and chief
executive officer of Tizona Therapeutics. All are leading experts in
oncology R&D.

“We are proud to bring in three leaders with extensive experience in
cancer research and development and an unwavering commitment to bringing
transformative, targeted medicines to patients,” said Barbara Weber,
M.D., Tango’s chief executive officer. “Their expertise, insights and
commitment to this field will help Tango immensely as we create a new
generation of breakthrough cancer therapies.”

Michael Pellini, M.D., MBA, joined Foundation Medicine as president and
chief executive in 2011 and transitioned to chairman last year. In
addition to his role at Foundation Medicine, Dr. Pellini is managing
partner of Section 32, a California-based technology and life sciences
venture fund (Section 32 is not a Tango investor). Dr. Pellini joined
Foundation Medicine from Clarient, Inc., which was acquired by GE
Healthcare in 2010, where he was president, chief operating officer and
served on its board of directors. A physician with over 20 years of
experience at the forefront of the clinical diagnostics and laboratory
industries, Dr. Pellini brings a depth of understanding of personalized
medicine, with a particular interest and focus in oncology. He serves as
a member of the board of directors for the Personalized Medicine
Coalition and the Mission Hospital Foundation (Provident/St. Joseph
Health), as well as several biotechnology companies. He is also a member
of the President’s Leadership Council for the Sydney Kimmel Medical
College at Thomas Jefferson University and the Advisory Board for
Mission Hospital’s Cancer Institute.

Allen Oliff, M.D., brings over three decades of experience in oncology
R&D to the Tango Board of Directors. He has held numerous leadership
positions at GSK and has led the development of seven marketed products
and two other agents in late-stage development, including the portfolio
of oncology drugs acquired by Novartis in 2015. Before joining GSK, Dr.
Oliff held leadership positions at DuPont Pharmaceuticals and Merck and
Co., where he was executive director of cancer research. Earlier in his
career, as an oncology researcher, he authored more than 120
peer-reviewed publications on the molecular pathogenesis of cancer, with
a focus on RNA tumor viruses, oncogenes and tumor suppressor genes.

Pablo Cagnoni, M.D., brings three decades of experience in developing
and commercializing life-changing medicines for cancer patients. He has
played a key role in bringing numerous oncology drugs to market,
including Tarceva, Afinitor, Kyprolis and Zykadia, among many others.
Dr. Cagnoni currently serves as president and CEO of Tizona
Therapeutics. He previously served as president of Onyx Pharmaceuticals,
where he had global strategic oversight of the business from early
product development through commercialization. Prior to moving to Onyx,
Dr. Cagnoni served as senior vice president and global head of clinical
development at Novartis Oncology, where he was responsible for all
late-stage clinical development for the oncology pipeline.

About Tango Therapeutics

Tango Therapeutics, a 2017 “Fierce 15” company, is a biotechnology
company developing novel therapies targeting context-dependent
vulnerabilities in cancers. Tango’s robust product engine is designed to
support the discovery and development of breakthrough medicines that
provide deeper, more sustained benefit than today’s targeted therapies,
and that extend the benefits of available immuno-oncology agents. The
company’s programs are focused in the area of synthetic lethality, the
interaction between two genes that causes cell death when both are
inactivated. Tango was launched in 2017 with a $55 million Series A
investment funded by Third Rock Ventures. For more information, please
visit www.tangotx.com.